Get started
Author

Vladislav O. Sarzhevskiy

Observed names: V. O. Sarzhevskiy, V. Sarzhevskiy, V.O. Sarzhevskiy, Vladislav O. Sarzhevskii, Vladislav Olegovich Sarzhevskii, Vladislav Olegovich Sarzhevskiy, Vladislav Sarzhevskiy
ORCID: 0000-0001-7164-6595
Observed ORCID: 0000-0001-7164-6595
OpenAlex ID: A5043375958
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study
2024 · Akihito Kawazoe, Rui-Hua Xu, et al. · Journal of Clinical Oncology · 115
PDF
P1091: Feasibility of Asct After Anti-pd-1 Therapy for R/r Classical Hodgkin Lymphoma
2022 · N. Mochkin, V. Sarzhevskiy, et al. · HemaSphere · 6
Checkpoint Inhibitors and Classical Hodgkin’s Lymphoma: Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Tumor (Experience at the NI Pirogov Russian National Medical Center of Surgery)
2021 · Vladislav Olegovich Sarzhevskii, E. A. Demina, et al. · Clinical oncohematology · 6
Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study
2022 · Ekaterina S. Nesterova, Aleksandra F. Saydullaeva, et al. · Journal of Modern Oncology · 5
PDF
Combined immunochemotherapy in patients with refractory/relapsed classical Hodgkin's lymphoma as a 2nd line treatment before autologous hematopoietic stem cell transplantation (preliminary results)
2022 · A. A. Mamedova, N. E. Mochkin, et al. · Oncohematology · 4
PDF
Ultrasound Ablation (HIFU) in the Treatment of Pancreatic Unresectable Tumors
2018 · O. E. Karpov, P. S. Vetshev, et al. · Annaly khirurgicheskoy gepatologii = Annals of HPB surgery · 4
PDF
Diagnostic and Prognostic Value of Biochemical Markers of Infectious Complications of High-Dose Therapy with Autologous Hematopoietic Stem Cell Transplantation in Malignant Lymphoproliferative Diseases
2017 · Vladislav Olegovich Sarzhevskii, Yu. N. Dubinina, et al. · Clinical oncohematology · 4
PDF
Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy
2021 · Ekaterina S. Nesterova, Tatyana Yu. Klitochenko, et al. · Journal of Modern Oncology · 3
PDF
High-dose chemotherapy following autologous hematopoietic stem cell transplantation for Hodgkin lymphoma. 10 years’ experience of the N.I. Pirogov National Medical and Surgical Center Ministry of Health of Russia
2017 · N. E. Mochkin, V. O. Sarzhevskiy, et al. · Russian Journal of Pediatric Hematology and Oncology · 3
PDF
Biochemical Markers of Cardiotoxicity of High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with Malignant Lymphoproliferative Disorders
2016 · Vladislav Olegovich Sarzhevskii, D. S. Kolesnikova, et al. · Clinical oncohematology · 3
PDF
Cardiotoxicity of High-Dose Chemotherapy with Autologous Hematopoietic Stem Cells Transplantation in Patients with Malignant Lymphomas. what is Worse - Beam or Cbv?
2014 · V. Sarzhevskiy, D. Kolesnikova, et al. · Annals of Oncology · 3
Evaluation of the effectiveness of hematopoietic blood stem cell mobilization using empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases: the experience of several centers in the Russian Federation. A retrospective study
2024 · Ekaterina S. Nesterova, Jana K. Mangasarova, et al. · Journal of Modern Oncology · 2
PDF
Use of electronic patient-reported outcome system in routine clinical practice in patients with lymphoproliferative neoplasms undergoing autologous hematopoietic stem cell transplantation: a feasibility study
2024 · Tatiana Nikitina, Vladimir Melnichenko, et al. · Cellular Therapy and Transplantation · 2
Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study
2024 · Ekaterina S. Nesterova, Aleksandra F. Saydullaeva, et al. · Journal of Modern Oncology · 2
PDF
Practice of inflammatory biomarkers for prediction of infectious complications after autologous hematopoietic stem cell transplantation
2025 · Yu. N. Dubinina, V. O. Sarzhevskiy, et al. · Oncohematology · 1
PDF
Development and Testing of Electronic Patient-Reported Outcome System “Health – Electronic Self-Assessment” (HESA) for Monitoring the Health Status of Patients with Hematologic Malignancies Based on Their Quality-of-Life Data
2024 · Tatyana Pavlovna Nikitina, V. Ya. Melnichenko, et al. · Clinical oncohematology · 1
PDF
Prognostic Value of Total Metabolic Tumor Volume (mtv) and Total Lesion Glycolysis (tlg) in Classic Hodgkin's Lymphoma Using an Automatic Method for Pathological Foci Segmentation
2022 · M.V. Metelkina, O.V. Mukhortova, et al. · Russian Electronic Journal of Radiology · 1
PDF
High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience
2020 · Nikita E. Mochkin, Vladislav O. Sarzhevskiy, et al. · Journal of Modern Oncology · 1
PDF
Ten-year experience of the Pirogov Center in the organization of oncological care in a multi-field hospital
2019 · Yu. L. Shevchenko, O. E. Karpov, et al. · Annaly khirurgicheskoy gepatologii = Annals of HPB surgery · 1
PDF
Obinutuzumab-Based Regimens in the First-Line Therapy for Follicular Lymphoma: Data from Real-World Clinical Practice in 41 Medical Institutions
2026 · Lali Galimovna Babicheva, G. S. Tumyan, et al. · Clinical oncohematology
PDF
Pharmacoeconomics of empegfilgrastim in patients with lymphoma receiving intensive chemotherapy to induce remission prior to high-dose therapy with autologous hematopoietic stem cell transplantation: a retrospective study
2026 · Vladislav O. Sarzhevskiy, Artur V. Halturin, et al. · Journal of Modern Oncology
PDF
High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in the Third- and Subsequent-Line Therapy for Relapsed/Refractory Classical Hodgkin Lymphoma
2026 · Vladislav Olegovich Sarzhevskiy, Yu. V. Protopopova, et al. · Clinical oncohematology
PDF
Efficacy and Tolerability of the PET-Guided Program BrECADD for Advanced Stages of Classical Hodgkin Lymphoma: Data from the Real-World Setting in Russia
2026 · Elena Andreevna Demina, O. S. Samoilova, et al. · Clinical oncohematology
PDF
The Use of Electronic Patient-reported Outcomes System «health - Electronic Self-assessment» (hesa) in Routine Clinical Practice for Health Status Monitoring in Patients With Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell Transplantation (auto-hsct)
2025 · T. P. Nikitina, V. Ya. Melnichenko, et al. · Bulletin of Pirogov National Medical & Surgical Center
PDF
851P Empegfilgrastim for prevention of infectious complications in patients with lymphomas during salvage chemotherapy before high-dose chemotherapy and autologous stem cell transplantation
2025 · V.O. Sarzhevskiy, A. Samoilova, et al. · Annals of Oncology
Works count: 31
Citation count: 167
H-index: 4
I10-index: 1
Year
Topic
Type